Royalty Pharma (RPRX) Debt Ratio (2019 - 2026)

Royalty Pharma has disclosed Debt Ratio across 8 years of filings, most recently posting 0.47 for Q2 2026.

• In Q2 2026, Debt Ratio fell 4.06% year-over-year to 0.47; the TTM figure through Jun 2026 stood at 0.47 (down 4.06% YoY), while the FY2025 annual figure was 0.48, up 0.65% from the prior year.
• Debt Ratio came in at 0.47 for Q2 2026 at Royalty Pharma, roughly flat from 0.47 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.49 in Q2 2025 to a low of 0.37 in Q4 2023.
• Average Debt Ratio over 5 years is 0.45, with a median of 0.47 recorded in 2024.
• Year-over-year, Debt Ratio retreated 23.29% in 2023 and rose 28.57% in 2025.
• Over 5 years, Debt Ratio stood at 0.49 in 2022, then dropped by 23.29% to 0.37 in 2023, then grew by 26.16% to 0.47 in 2024, then grew by 0.65% to 0.48 in 2025, then retreated by 0.89% to 0.47 in 2026.
• Per Business Quant data, the three most recent Debt Ratio figures were 0.47 in Q2 2026, 0.47 in Q1 2026, and 0.48 in Q4 2025.